Publications by authors named "J P Shepard"

Objective: To understand parents' experiences of ethical challenges in the care of children with chronic and serious medical conditions and what resources they access for support.

Study Design: We recruited English-speaking parents of children with complex and serious medical conditions via family advocacy groups to complete an electronic survey from October 2022 through February 2023. We queried respondents' experiences with specific ethical challenges in the care of their child, whether their concerns persisted, and what resources they accessed.

View Article and Find Full Text PDF

Background: Biotechnologies that utilize microorganisms as production hosts for lipid synthesis will enable an efficient and sustainable solution to produce lipids, decreasing reliance on traditional routes for production (either petrochemical or plant-derived) and supporting a circular bioeconomy. To realize this goal, continuous biomanufacturing processes must be developed to maximize productivity and minimize costs compared to traditional batch fermentation processes.

Results: Here, we utilized biofilms of the marine bacterium, Marinobacter atlanticus, to produce wax esters from succinate (i.

View Article and Find Full Text PDF

Phospholipase C gamma 2 (PLCγ2) plays important roles in cell signaling downstream of various membrane receptors. PLCγ2 contains a multidomain inhibitory region critical for its regulation, while it has remained unclear how these domains contribute to PLCγ2 activity modulation. Here we determined three structures of human PLCγ2 in autoinhibited states, which reveal dynamic interactions at the autoinhibition interface, involving the conformational flexibility of the Src homology 3 (SH3) domain in the inhibitory region, and its previously unknown interaction with a carboxyl-terminal helical domain in the core region.

View Article and Find Full Text PDF
Article Synopsis
  • Clesrovimab is a new monoclonal antibody designed to prevent respiratory syncytial virus (RSV) disease in infants, tested in a study with 183 healthy infants aged 2 weeks to 8 months.
  • The study found that Clesrovimab was well tolerated, with the most common side effect being irritability, and it demonstrated a long half-life of 44.9 days, along with improved serum neutralizing antibodies over time.
  • Infants who received Clesrovimab had lower rates of RSV-related illnesses compared to those given a placebo, indicating its potential effectiveness for further development in clinical trials.
View Article and Find Full Text PDF